Ligand id: 6770

Name: alemtuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alemtuzumab

No information available.
Summary of Clinical Use
Alemtuzumab is primarily used for the treament of relapsing-remitting multiple sclerosis (RRMS). Based on results from clinical trials, the UK National Institute for Health and Care Excellence (NICE) approved use of this drug for RRMS in May 2014. In November 2014, the US FDA approved alemtuzumab for RRMS. A list of clinical trials for this drug in MS patients is available using this link to

Alemtuzumab can also be used in B-cell chronic lymphocytic leukemia (CLL) therapy and in transplant indications, but access for these indications is controlled through a patient access programme (in the UK).

Results from Phase 3 trial NCT00548405, suggest that treating RRMS patients with alemtuzumab earlier can actually improve preexisiting disability, rather than just slowing disease progression (with caveats around risk-benefit, and the serious side-effects of alemtuzumab therapy; side-effects such as infusion associated reactions, infections, and development of other autoimmune diseases) [3].
Mechanism Of Action and Pharmacodynamic Effects
Hypothesised to act via the activation of antibody-dependent cell-mediated cytotoxicity.
External links